BR112015003032A2 - anticorpos anti-jagged e métodos de utilização'. - Google Patents
anticorpos anti-jagged e métodos de utilização'.Info
- Publication number
- BR112015003032A2 BR112015003032A2 BR112015003032A BR112015003032A BR112015003032A2 BR 112015003032 A2 BR112015003032 A2 BR 112015003032A2 BR 112015003032 A BR112015003032 A BR 112015003032A BR 112015003032 A BR112015003032 A BR 112015003032A BR 112015003032 A2 BR112015003032 A2 BR 112015003032A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- jagged antibodies
- jagged
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261682640P | 2012-08-13 | 2012-08-13 | |
US61/682,640 | 2012-08-13 | ||
US201361784332P | 2013-03-14 | 2013-03-14 | |
US61/784,332 | 2013-03-14 | ||
PCT/US2013/054664 WO2014028446A1 (en) | 2012-08-13 | 2013-08-13 | Anti-jagged anitbodies and methods of use |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112015003032A2 true BR112015003032A2 (pt) | 2017-12-12 |
BR112015003032A8 BR112015003032A8 (pt) | 2018-04-10 |
BR112015003032B1 BR112015003032B1 (pt) | 2023-03-28 |
Family
ID=49004047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015003032-7A BR112015003032B1 (pt) | 2012-08-13 | 2013-08-13 | Anticorpos isolados, imunoconjugado, formulação farmacêutica e uso do anticorpo |
Country Status (11)
Country | Link |
---|---|
US (4) | US10113002B2 (pt) |
EP (1) | EP2882776B1 (pt) |
JP (4) | JP6352264B2 (pt) |
KR (2) | KR102193080B1 (pt) |
CN (1) | CN104520328B (pt) |
BR (1) | BR112015003032B1 (pt) |
CA (1) | CA2880271C (pt) |
HK (1) | HK1209432A1 (pt) |
MX (1) | MX357675B (pt) |
RU (2) | RU2018130986A (pt) |
WO (1) | WO2014028446A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9663573B2 (en) | 2011-10-05 | 2017-05-30 | Genentech, Inc. | Methods of treating liver conditions using Notch2 antagonists |
AU2013278075B2 (en) | 2012-06-22 | 2018-05-17 | Cytomx Therapeutics, Inc. | Anti-jagged 1/Jagged 2 cross-reactive antibodies, activatable anti-Jagged antibodies and methods of use thereof |
WO2014028446A1 (en) | 2012-08-13 | 2014-02-20 | Genentech, Inc. | Anti-jagged anitbodies and methods of use |
US10350216B2 (en) * | 2013-01-14 | 2019-07-16 | The Trustees Of Columbia University In The City Of New York | Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders |
JP6527132B2 (ja) | 2013-03-15 | 2019-06-05 | ジェネンテック, インコーポレイテッド | 肝臓がんの診断及び治療のための組成物及び方法 |
AU2015217271B2 (en) | 2014-02-12 | 2018-10-25 | Genentech, Inc. | Anti-Jagged1 antibodies and methods of use |
EP3166627A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Notch pathway inhibition |
JOP20190259A1 (ar) | 2017-05-31 | 2019-10-31 | Amgen Inc | بروتينات ربط مولد ضد مضادة لـ jagged1 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6004924A (en) | 1991-12-11 | 1999-12-21 | Imperial Cancer Research Technology, Ltd. | Protein sequences of serrate gene products |
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US7667004B2 (en) | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
US20030170636A1 (en) * | 2002-03-05 | 2003-09-11 | Isis Pharmaceuticals Inc. | Antisense modulation of jagged 2 expression |
US20030185829A1 (en) * | 2002-03-12 | 2003-10-02 | Erich Koller | Jagged 2 inhibitors for inducing apoptosis |
US20040101847A1 (en) | 2002-11-22 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of Notch2 expression |
US20050191302A1 (en) | 2002-08-29 | 2005-09-01 | University Of Southampton | Treatment for liver disease |
AU2003295471B2 (en) | 2002-11-15 | 2011-08-25 | Genmab A/S | Human monoclonal antibodies against CD25 |
AU2003298816C1 (en) | 2002-12-02 | 2010-12-16 | Amgen Fremont, Inc. | Antibodies directed to Tumor Necrosis Factor and uses thereof |
US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
EP1709150A4 (en) * | 2003-11-26 | 2007-11-21 | Health Research Inc | USE OF NOTCH-INTERFERING MEDICAMENTS FOR THE TREATMENT OF PLASMA-CELL-RELATED DISEASES |
KR20160096228A (ko) | 2004-07-22 | 2016-08-12 | 제넨테크, 인크. | Her2 항체 조성물 |
US7423128B2 (en) * | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
AT502055B1 (de) | 2005-06-21 | 2007-11-15 | Univ Wien Med | Anti tumor medikament |
US20080241150A1 (en) | 2006-05-15 | 2008-10-02 | The Brigham And Women's Hospital, Inc. | Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1 |
US7935791B2 (en) | 2006-12-18 | 2011-05-03 | Genentech, Inc. | Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases |
CA2676008A1 (en) | 2007-01-24 | 2008-07-31 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
CA2676766A1 (en) | 2007-02-09 | 2008-08-21 | Genentech, Inc. | Anti-robo4 antibodies and uses therefor |
EP2155249A4 (en) * | 2007-05-15 | 2011-11-16 | Oncomed Pharm Inc | COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER |
PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
ME00977B (me) | 2007-08-10 | 2012-06-20 | Regeneron Pharma | Humana antitijela visokog afiniteta prema humanom nervnom faktoru rasta |
JP2009078998A (ja) * | 2007-09-26 | 2009-04-16 | Univ Of Tokushima | Jagged2を用いる制癌剤 |
CN102056945A (zh) * | 2008-04-07 | 2011-05-11 | 埃博灵克斯股份有限公司 | 针对Notch途径的单可变结构域 |
MY155603A (en) | 2008-07-08 | 2015-11-13 | Oncomed Pharm Inc | Notch-binding agents and antagonists and methods of use thereof |
EP2927244A1 (en) | 2008-09-19 | 2015-10-07 | MedImmune, LLC | Antibodies directed to DLL4 and uses thereof |
AR073717A1 (es) | 2008-10-01 | 2010-11-24 | Genentech Inc | Anticuerpos anti-notch2 de murino y humano, y metodos de uso |
RU2636046C2 (ru) | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
US8945569B2 (en) * | 2009-11-19 | 2015-02-03 | Oncomed Pharmaceuticals, Inc. | Jagged-binding agents and uses thereof |
US9663573B2 (en) | 2011-10-05 | 2017-05-30 | Genentech, Inc. | Methods of treating liver conditions using Notch2 antagonists |
AU2013278075B2 (en) | 2012-06-22 | 2018-05-17 | Cytomx Therapeutics, Inc. | Anti-jagged 1/Jagged 2 cross-reactive antibodies, activatable anti-Jagged antibodies and methods of use thereof |
WO2014028446A1 (en) | 2012-08-13 | 2014-02-20 | Genentech, Inc. | Anti-jagged anitbodies and methods of use |
JP6527132B2 (ja) | 2013-03-15 | 2019-06-05 | ジェネンテック, インコーポレイテッド | 肝臓がんの診断及び治療のための組成物及び方法 |
AU2015217271B2 (en) | 2014-02-12 | 2018-10-25 | Genentech, Inc. | Anti-Jagged1 antibodies and methods of use |
EP3166627A1 (en) * | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Notch pathway inhibition |
-
2013
- 2013-08-13 WO PCT/US2013/054664 patent/WO2014028446A1/en active Application Filing
- 2013-08-13 US US14/421,103 patent/US10113002B2/en active Active
- 2013-08-13 RU RU2018130986A patent/RU2018130986A/ru unknown
- 2013-08-13 KR KR1020157006164A patent/KR102193080B1/ko active IP Right Grant
- 2013-08-13 EP EP13751040.0A patent/EP2882776B1/en active Active
- 2013-08-13 RU RU2015108797A patent/RU2666990C2/ru active
- 2013-08-13 BR BR112015003032-7A patent/BR112015003032B1/pt active IP Right Grant
- 2013-08-13 MX MX2015001942A patent/MX357675B/es active IP Right Grant
- 2013-08-13 CA CA2880271A patent/CA2880271C/en active Active
- 2013-08-13 CN CN201380041607.8A patent/CN104520328B/zh active Active
- 2013-08-13 KR KR1020207035928A patent/KR20200143502A/ko not_active Application Discontinuation
- 2013-08-13 JP JP2015526762A patent/JP6352264B2/ja active Active
-
2015
- 2015-10-14 HK HK15110047.5A patent/HK1209432A1/xx unknown
-
2018
- 2018-04-23 JP JP2018082543A patent/JP6619047B2/ja active Active
- 2018-09-20 US US16/136,478 patent/US10689455B2/en active Active
-
2019
- 2019-11-12 JP JP2019204815A patent/JP7366700B2/ja active Active
-
2020
- 2020-05-12 US US16/872,631 patent/US11702479B2/en active Active
-
2021
- 2021-08-11 JP JP2021131076A patent/JP2021191275A/ja not_active Withdrawn
-
2023
- 2023-05-22 US US18/321,249 patent/US20240034805A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016001102A1 (es) | Anticuerpos anti-claudina novedosos y métodos de uso. | |
CO7071096A2 (es) | Anticuerpos anti-lgr5 e inmunoconjugados | |
CL2015001266A1 (es) | Anticuerpos de antihemaglutinina y métodos de uso. | |
BR112015002193A2 (pt) | anticorpos anti-etbr e imunoconjugados | |
HK1209373A1 (en) | Anti-ly6e antibodies and immunoconjugates and methods of use ly6e | |
BR112014017749A2 (pt) | Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo | |
CL2015000027A1 (es) | Anticuerpos e inmunoconjugados anti-cd22 | |
DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
BR112014012137A2 (pt) | anticorpos anti-fgfr2 e suas utilizações | |
ZA201501858B (en) | Anti-mcam antibodies and associated methods of use | |
BR112015003838A2 (pt) | formulações de anticorpo e proteína | |
DK3381943T3 (da) | Anti-kit-antistoffer og anvendelser deraf | |
DK2850101T3 (da) | Anti-FcRn-antistoffer | |
DK2580243T3 (da) | Antibodies against human cd38 | |
IL238227A0 (en) | Antibodies against c16orf54 and uses thereof | |
CO7020870A2 (es) | Anticuerpos anti-htra1 y métodos de uso | |
BR112013002297A2 (pt) | anticorpos humanizados seguros e funcionais | |
CO7000747A2 (es) | Anticuerpos anti-lrp5 y métodos de uso | |
BR112015003032A2 (pt) | anticorpos anti-jagged e métodos de utilização'. | |
BR112014002716A2 (pt) | anticorpos anti-poliubiquitina e métodos de uso | |
DK3453723T3 (da) | Anti-ASIC1-antistoffer og anvendelser deraf | |
BR112014000049A2 (pt) | pirrolotriazinas substituídas com hidroximelilarilo e sua utilização | |
EP2938632A4 (en) | ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE | |
CL2014003125A1 (es) | Anticuerpos de anti-transglutaminasa 2 | |
DK2828292T3 (da) | Jcv-neutraliserende antistoffer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/08/2013, OBSERVADAS AS CONDICOES LEGAIS |